◎记者 柴刘斌 冯心怡 真金白银的分红、豪气的回购增持、灵活的股权激励、高频次的机构调研、包容的并购重组、活跃的海 外投资……这一年，一批民营上市公司通过一系列市场化工具的"组合拳"，积极探索市值管理"最优 解"。 据Wind数据统计，截至2025年11月14日，已有512家民企上市公司披露了市值管理制度，其中约70家公 司市值增幅超50%，电力设备、机械设备、有色金属等行业表现尤为突出。 "民企市值管理行为更为灵活多样，善于利用股权激励、并购重组、投资新兴产业等方式。但受制于资 源与融资环境，产业龙头更注重战略叙事和全球化布局，中小民企则更关注流动性管理和股权再融 资。"近日，上海财经大学滴水湖高级金融学院教授、资本市场研究中心主任陈欣接受上海证券报记者 采访，分析了不同规模民企做好市值管理的差异化打法。 强化价值沟通 提振市场信心 埃斯顿一年40多次接待机构调研，迈瑞医疗年内实施3次大手笔分红，指南针发布涵盖422名员工的股权 激励计划……这一年，民营企业正将市值管理从理念转化为行动。 *ST松发市值管理制度发布以来市值增幅达1546.87%，东山精密1亿欧元收购GMD集团加快欧洲产业布 局，宁德时代匈牙 ...

Core Viewpoint - The Medical Health Index (980016) closed at 6572.66 points, down 0.65%, with a trading volume of 23.397 billion yuan and a turnover rate of 0.87% on November 14 [1] Group 1: Index Performance - Among the index constituents, 16 stocks rose while 33 stocks fell, with Ganli Pharmaceutical leading the gainers at a 2.0% increase and Yirui Technology leading the decliners at a 3.74% decrease [1] - The top ten constituents of the Medical Health Index include major companies such as WuXi AppTec, Hengrui Medicine, and Mindray Medical, with respective weights of 13.66%, 11.00%, and 7.57% [1] Group 2: Market Capitalization and Stock Prices - The total market capitalization of the top ten constituents ranges from 553.09 billion yuan for Kelun Pharmaceutical to 4603.55 billion yuan for Rihai Shenzhou, with stock prices varying from 12.25 yuan to 298.80 yuan [1] - The performance of the top ten stocks shows a mix of slight declines, with WuXi AppTec down 1.49% and Hengrui Medicine down 1.04% [1] Group 3: Capital Flow - The Medical Health Index constituents experienced a net outflow of 472 million yuan from major funds, while retail investors saw a net inflow of 388 million yuan [1] - Detailed capital flow data indicates that Ganli Pharmaceutical had a net inflow of 62.98 million yuan from major funds, despite a net outflow from retail investors [2]

Group 1 - The core transaction on November 14 involved a block trade of 30,900 shares of Mindray Medical, with a transaction value of 5.4625 million yuan, at a price of 176.78 yuan, representing a discount of 14.89% compared to the closing price of the day [2][3] - Over the past three months, Mindray Medical has recorded a total of 13 block trades, amounting to a cumulative transaction value of 232 million yuan [2] - The closing price of Mindray Medical on the day of the transaction was 207.70 yuan, reflecting a slight decline of 0.24%, with a daily turnover rate of 0.43% and a total trading volume of 1.08 billion yuan [2] Group 2 - The latest margin financing balance for Mindray Medical stands at 4.114 billion yuan, having decreased by 118 million yuan over the past five days, which is a decline of 2.78% [3] - Mindray Medical was established on January 25, 1999, with a registered capital of 12.124 billion yuan [3]

| 权益类证券大宗交易(协议交易) | | | | | | | 团 下载 | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易日期 | 证券代码 | 证券简称 | 成交价格 (元) | 成交量 (万股/万份) | 成交金额 (万元) | 买方营业部 | 卖方营业部 | | 2025-11-14 | 300760 | 迈瑞医疗 | 176.78 | 3.09 | | 546.25 招商证券股份有限 | 申万宏源证券有限 | | | | | | | | 公司深圳蛇口工业 三路证券营业部 | 公司安徽分公司 | 11月14日，迈瑞医疗大宗交易成交3.09万股，成交额546.25万元，占当日总成交额的0.5%，成交价 176.78元，较市场收盘价207.7元折价14.89%。 ...

丨证券研究报告丨 [Table_scodeMsg1] 公司研究丨点评报告丨迈瑞医疗（300760.SZ） [Table_Title] 业绩符合预期，收入拐点已现 报告要点 [Table_Summary] 业绩符合预期，收入迎来增长拐点。公司 2025 年第三季度营业收入 90.91 亿元，同比增长 1.53%；经营性现金流 33.51 亿元，同比增长 30.02%，主要是由于国内市场 2025 年上半年设 备招标活动恢复，营业收入同比降幅明显收窄，四季度业绩有望延续环比持续改善的趋势，国 内业务 2026 年有望回归正增长。2025 年第三季度海外市场提速，收入占比超过 50%。2025 年第三季度公司海外收入增长 11.9%，回到双位数增长水平，其中欧洲市场增长 29%。 分析师及联系人 [Table_Author] 彭英骐 徐晓欣 SAC：S0490524030005 SAC：S0490522120001 SFC：BUZ392 请阅读最后评级说明和重要声明 %% %% %% %% research.95579.com 1 [Table_scodeMsg2] 迈瑞医疗（300760.SZ） cjzqdt11 ...

Core Viewpoint - The ChiNext Index has experienced a decline of 1.78% as of November 14, 2025, with mixed performance among constituent stocks, indicating volatility in the market driven by momentum reversal effects and core asset accumulation [1] Group 1: Market Performance - The leading stocks include QianDao Intelligent, which rose by 5.76%, and YiHuaLu, which increased by 3.99%, while JiangBoLong fell by 9.26% [1] - The ChiNext ETF (159908) decreased by 1.62%, with the latest price at 2.92 yuan, but has seen a cumulative increase of 3.99% over the past month [1] - The trading volume for the ChiNext ETF was 14.02 million yuan, with a turnover rate of 1.13% [1] Group 2: Valuation and Economic Signals - Current market valuation levels are near historical averages, with clearer signals of macroeconomic recovery emerging [1] - The analysis suggests that the ChiNext Index has a relatively certain horizontal comparison in terms of allocation space, particularly in the new energy sector, which is a focus area for reversing internal competition [1] - Prices for upstream silicon materials have stabilized, but downstream demand may face challenges related to commercial inventory, leading to market uncertainty [1] Group 3: ETF and Index Composition - The latest scale of the ChiNext ETF is 1.248 billion yuan, closely tracking the ChiNext Index, which consists of 100 stocks with high market capitalization and liquidity [2] - As of October 31, 2025, the top ten weighted stocks in the ChiNext Index account for 58.2% of the index, including companies like Ningde Times and Zhongji Xuchuang [2]

Core Insights - The healthcare innovation sector is showing positive momentum, with the China Securities Medicine and Medical Device Innovation Index (931484) rising by 0.31% as of November 14, 2025, and several key stocks, including Sanofi and Ganli Pharmaceutical, experiencing significant gains [1] Group 1: Market Performance - The China Securities Medicine and Medical Device Innovation Index has seen a 0.31% increase, with notable stock performances: Sanofi up 4.64%, Ganli Pharmaceutical up 3.28%, and Jiutian Pharmaceutical up 1.83% [1] - The Medical Innovation ETF (516820) has also risen by 0.26%, marking its third consecutive increase [1] Group 2: Clinical Developments - AstraZeneca announced successful Phase III clinical trials for Baxdrostat, which significantly reduced 24-hour average systolic blood pressure in patients with resistant hypertension over 12 weeks, indicating a new treatment pathway for hypertension [1] Group 3: Industry Trends - According to Dongfang Caifu Securities, the pharmaceutical industry showed improvement in Q3 2025, with the medical device sector experiencing a turning point, achieving positive year-on-year revenue growth and a notable narrowing of net profit declines [1] - The CXO sector performed exceptionally well in the first three quarters of 2025, with medical R&D outsourcing revenue increasing by 12.2% and net profit rising by 56.8%, particularly in ADC CDMO and peptide CDMO fields [2] - The index reflects the performance of 30 profitable and growth-oriented companies in the pharmaceutical and medical device sectors, with the top ten stocks accounting for 64.12% of the index [2]

格隆汇11月13日｜中信建投证券研报指出，迈瑞医疗Q3业绩符合预期，收入增速如期转正，利润端受 毛利率下降、费用率提升影响有所承压。Q4收入增速预计较Q3进一步提升，Q4利润预计在低基数下实 现增长，但考虑到前三季度利润下滑幅度较大，且今年整体利润率承压，预计全年公司归母净利润将有 双位数下滑。展望明年，预计公司将走出行业外部压力带来的影响，回归收入、利润稳健增长轨道。中 长期来看，公司重视研发创新和国际化，拥有高效的研发体系和优秀的渠道管理能力，外延并购有望进 一步拓展布局，加上公司国际化进度持续推进，该行看好公司未来加快迈向全球医疗器械Top10 公司的 步伐。维持"买入"评级。 ...

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector, indicating a positive outlook for investment opportunities in this industry [4]. Core Insights - The pharmaceutical sector is experiencing performance divergence, with the medical device segment showing signs of a turning point [1]. - For the first three quarters of 2025, the total revenue of 461 A-share pharmaceutical companies was CNY 17,876.4 billion, a year-on-year decrease of 2%, while net profit attributable to shareholders was CNY 1,435.7 billion, down 6.43% year-on-year [10][29]. - In Q3 2025, the industry showed signs of improvement, with total revenue reaching CNY 5,936.9 billion, a year-on-year increase of 0.51%, and net profit of CNY 419.4 billion, down only 0.95% year-on-year [33]. Summary by Sections 1. Market Review - The pharmaceutical and biotechnology index increased by 21.1% year-to-date, outperforming the CSI 300 index by 3.17 percentage points, with the medical services sub-sector showing the highest growth at 40.25% [17]. 2. Industry Performance - The medical commercial and medical service sectors are the only segments showing positive revenue growth in the first three quarters of 2025, with revenues of CNY 7,723.1 billion and CNY 1,374.9 billion, respectively [29]. - The chemical preparation and medical service sectors demonstrated significant profit growth in Q3, with net profits increasing by 10.43% and 25.80%, respectively [33]. 2.1 Raw Materials and Auxiliary Drugs - The raw materials sector reported total revenue of CNY 670.65 billion, down 7.56% year-on-year, with net profit of CNY 61.01 billion, down 11.18% year-on-year [35]. - The report suggests focusing on high-quality raw material companies such as Shanhe Pharmaceutical and Weier Pharmaceutical [42]. 2.2 Chemical Preparations & Innovative Drugs - The chemical preparations sector achieved total revenue of CNY 3,050.25 billion, down 3.79% year-on-year, with net profit of CNY 320.73 billion, down 15.09% year-on-year [43]. - The report highlights the significant growth of innovative drugs, with 43 new drugs approved in the first half of 2025, a 59% increase year-on-year [47]. 2.3 Traditional Chinese Medicine - The traditional Chinese medicine sector reported total revenue of CNY 2,512.22 billion, down 3.84% year-on-year, with net profit of CNY 292.63 billion, down 1.16% year-on-year [49]. - The sector is transitioning towards quality-oriented development, with a focus on improving the quality of raw materials [57]. 2.4 Biological Products - The biological products sector reported total revenue of CNY 802.59 billion, down 15.34% year-on-year, with net profit of CNY 123.48 billion, down 28.73% year-on-year [58]. - The report suggests monitoring companies with strong internationalization efforts, such as Kangtai Biological [62]. 2.5 Medical Commerce - The medical commerce sector achieved total revenue of CNY 7,723.15 billion, up 0.56% year-on-year, with net profit of CNY 160.9 billion, up 4.94% year-on-year [63]. - The report emphasizes the importance of diversified development in pharmacies, supported by national policies promoting health consumption [68].

Core Viewpoint - The company, Mindray Medical, has submitted its application for a Hong Kong IPO, aiming to enhance its global presence and innovation capabilities through the raised funds [1][4]. Group 1: IPO and Fund Utilization - The IPO will combine public offerings in Hong Kong with international placements, with the specific scale to be determined based on market conditions [1]. - The funds raised will primarily be used for increasing global R&D investment, exploring potential global mergers and acquisitions, and enhancing the global sales network and supply chain capabilities [1][4]. Group 2: Business Development and Market Position - Mindray Medical is a leading global medical device company, covering multiple product lines and holding a significant market share in various segments [2]. - The company is projected to achieve a revenue of 36.7 billion yuan in 2024, with a compound annual growth rate (CAGR) of over 18% from 2017 to 2024 [2]. Group 3: R&D and M&A Strategy - As of June 30, 2025, the company plans to invest approximately 12.8 billion yuan in R&D, with over 5,200 specialized R&D personnel and a significant number of patents filed [3]. - Mindray has actively pursued acquisitions since its A-share listing, including notable purchases of companies in Finland, Germany, and China to enhance its product offerings and supply chain [3]. Group 4: Globalization and Market Opportunities - The global medical device market is expected to grow from $456.6 billion in 2020 to $623 billion in 2024, with a CAGR of 8.1% [5]. - Mindray has established a comprehensive global network, with localized production in 11 countries and a significant international workforce, enhancing its operational resilience and market responsiveness [6]. Group 5: Competitive Position and Future Outlook - Mindray's international revenue reached 16.4 billion yuan in 2024, with over 50% of its revenue coming from international markets as of Q3 2025 [6]. - The company has improved its global ranking in the medical device industry, moving from 36th in 2020 to 23rd in 2023, indicating a positive trajectory in market competitiveness [7].